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AbstrAct
Objective To present meta-analytic test accuracy 
estimates of levels of antitumour necrosis factor (anti-TNF) 
and antibodies to anti-TNF to predict loss of response 
or lack of regaining response in patients with anti-TNF 
managed Crohn’s disease.
Methods MEDLINE, Embase, the Cochrane Library and 
Science Citation Index were searched from inception to 
October/November 2014 to identify studies which reported 
2×2 table data of the association between levels of anti-TNF 
or its antibodies and clinical status. Hierarchical/bivariate 
meta-analysis was undertaken with the user-written 
‘metandi’ package of Harbord and Whiting using Stata V.11 
software, for infliximab, adalimumab,anti-infliximab and 
anti-adalimumab levels as predictors of loss of response. 
Prevalence of Crohn’s disease in included studies was 
meta-analysed using a random effects model in MetaAnalyst 
software to calculate positive and negative predictive values. 
The search was updated in January 2017.
Results 31 studies were included in the review. Studies 
were heterogeneous with respect to the type of test used, 
criteria for establishing response and loss of response, 
population examined and results. Meta-analytic summary 
point estimates for sensitivity and specificity were 65.7% 
and 80.6% for infliximab trough levels and 56% and 79% 
for antibodies to infliximab, respectively. Pooled results for 
adalimumab trough levels and antibodies to adalimumab 
were similar. Pooled positive and negative predictive 
values ranged between 70% and 80% implying that 
between 20% and 30% of both positive and negative test 
results may be incorrect in predicting loss of response.
Conclusion The available evidence suggests that these 
tests have modest predictive accuracy for clinical status; 
direct test accuracy comparisons in the same population 
are needed. More clinical trial evidence from test–treat 
studies is required before the clinical utility of the tests can 
be reliably evaluated.
IntroductIon
Antitumour necrosis factor (anti-TNFα) 
agents, including infliximab (Remicade, Merck 
Sharp & Dohme) and adalimumab (Humira, 
AbbVie), are well-established second-line or 
third-line therapies for people with Crohn’s 
disease (CD). Failure to respond during induc-
tion therapy and loss of response (LOR) after 
initial success are widely documented.1–5 
One suggested mechanism for this is the 
production of antibodies which neutralise 
the anti-TNFα agents and hasten their clear-
ance from the circulation, thus reducing 
drug availability. The treatment strategy for 
LOR is usually to escalate the drug dosage or 
to shorten the dosage interval. If this fails, a 
switch to an alternative anti-TNF agent can be 
tried in order to minimise the influence of anti-
drug antibodies directed against the first agent. 
Another suggested underlying mechanism for 
LOR is that cytokines other than TNFα may 
become the major inflammatory agents. This 
suggestion arises from the observation that 
some patients have a LOR to anti-TNF despite 
the presence of therapeutic drug levels and 
an absence of anti-TNF antibodies. For such 
patients, the continued use of anti-TNFs may 
be considered futile and a switch to different 
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Research
Strengths and limitations of this study
 ► This is the first study to summarise predictive 
accuracy of tests for loss of response to antitumour 
necrosis factor drugs for managing Crohn’s disease, 
in a clinically relevant manner.
 ► We included more studies than previous meta-
analyses.
 ► We investigated drug and antibody levels for both 
infliximab and adalimumab.
 ► Many of the included studies had a high risk of bias.
 ► There was insufficient data for subgroup analyses 
for some types of test.
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biological therapies or other agents may represent the 
preferred strategy.
The potential role of anti-TNF antibodies and of 
subtherapeutic drug levels in LOR has provided the 
impetus for the development of assays for both anti-TNF 
drugs and for antibodies, and a plethora of studies using 
such assays have been produced, exploring the associ-
ation between either levels of antibodies to anti-TNF 
agents and clinical response or levels of drugs and clinical 
response. Studies have measured LOR to the adminis-
tered anti-TNF agent or failure to regain response after 
a change in treatment. By dichotomising the outcomes 
at various detectable levels of drug and of antibodies to 
anti-TNF, the diagnostic value of these tests in predicting 
LOR or lack of regaining response has been assessed.
Several authors have meta-analysed studies which have 
reported the association between levels of antibodies to 
anti-TNF agents and clinical status.6–9 These authors have 
presented pooled relative risk or odds ratio (OR) statis-
tics for clinical state (eg, response or LOR) investigating 
positive versus negative test result patients (ie, antibodies 
to anti-TNF agent present or absent), or conversely for 
test result (positive or negative) in patients with response 
versus those without response. Although these pooled 
statistics provide useful information on the association 
between antibody levels and clinical status, they do not 
address the question of test accuracy when tests are used 
as a predictor of patients’ clinical response status which 
is the perspective likely to be adopted by clinicians for 
patients receiving treatment that may be predicated on 
test results. Primary studies frequently report test accuracy 
analysis such as receiver operating characteristic (ROC) 
curves and test accuracy measures such as sensitivity and 
specificity. When viewed as diagnostic tests,10 it becomes 
possible to perform alternative meta-analysis so as to 
obtain pooled estimates of test accuracy. The predictive 
accuracy of such tests is of considerable practical interest. 
Our objective therefore is to present the meta-analytic 
results in terms of pooled test accuracy estimates. A 
particular advantage of this method is that it allows for 
investigation of the covariance of associations or, from the 
perspective of a predictive test, the covariance between 
sensitivity and specificity, thus giving a more complete 
picture of the value of these tests in clinical practice.
Methods
search for studies
An iterative procedure was used to develop the initial 
MEDLINE search, which was subsequently adapted 
appropriately for other databases and online resources. 
We searched multiple bibliographic databases including 
MEDLINE, Embase, the Cochrane Library and Science 
Citation Index from inception to October/November 
2014. Searches of other online resources including trial 
registries were also undertaken. Full details of the search 
strategies used, with exact search dates, are provided 
in the online supplement 1 . Reference lists of included 
studies and relevant review articles were checked. Citation 
searches of selected included studies were undertaken. 
An update of the search was undertaken in January 2017 
(see online supplement 2 figure 1 and table 1) .
study eligibility criteria
We included studies of patients with CD treated with 
infliximab or adalimumab. Studies with mixed Crohn’s 
and ulcerative colitis populations were included if the 
proportion of Crohn’s patients was at least 70%. The 
intervention of interest was a test measuring serum 
anti-TNFα (infliximab or adalimumab) and/or anti-in-
fliximab or anti-adalimumab antibody levels. Studies 
reporting clinical status (ie, response or lack of response) 
as an outcome were eligible for inclusion. The reported 
results had to allow for cross-tabulation of dichotomous 
test outcome with clinical status by means of 2×2 tables 
in order to calculate the diagnostic test accuracy parame-
ters. All primary study designs were included.
study selection
Two reviewers independently assessed titles and abstracts 
for inclusion using a prepiloted form. All potentially 
relevant publications were retrieved and examined 
independently. Any disagreements regarding inclu-
sion/exclusion were discussed and resolved with a third 
reviewer. The study selection process and reasons for 
exclusion at full text screening level are presented in the 
PRISMA study flow diagram (see figure 1).
Quality assessment
Studies were quality assessed using a modified QUADAS-2 
checklist.11 Items included were method of patient 
selection, blinding of index test results, exclusion of unin-
terpretable test results from 2×2 table data and method of 
assessment of clinical status (the reference case).
evidence synthesis and statistical methods
Patient numbers within extracted 2×2 data tables were used 
to generate Forest plots of paired sensitivity and specificity 
(accompanied by 95% CIs) using Review Manager (RevMan 
V.5.1; Nordic Cochrane Centre, Copenhagen, Denmark) 
for four different tests: (1) infliximab levels as predictor of 
loss of or lack of regaining response, (2) antibodies to inflix-
imab as predictor of loss of or lack of regaining response, 
(3) adalimumab levels as predictor of loss of or lack of 
regaining response and (4) antibodies to adalimumab as 
predictor of loss of or lack of regaining response. Hierar-
chical/bivariate12 meta-analysis was undertaken with the 
user-written ‘metandi’ package of Harbord and Whiting13 
using Stata V.11 software. Positive and negative predictive 
values were calculated14 at the pooled prevalence of LOR 
in the test population. Prevalence was meta-analysed using 
a random effects model in MetaAnalyst software.15 For 
meta-analyses which incorporated 10 or more studies, we 
examined the risk of publication bias (see online supple-
ment 3) mindful of the caveats relating to this in diagnostic 
test accuracy studies.16
group.bmj.com on July 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Freeman K, et al. BMJ Open 2017;7:e014581. doi:10.1136/bmjopen-2016-014581
Open Access
Figure 1 PRISMA study flow diagram.
The protocol for this review was registered on PROS-
PERO 2014:CRD42014015278. The full protocol is 
included in the  online supplementary appendix 1.
results
We identified 2429 records of which 31 were eligible for 
inclusion (see online supplement 4 table 1 for excluded 
studies with reason). Of these, 24 were full-text reports 
and 7 were conference abstracts. The PRISMA flow 
diagram is detailed in figure 1. Eleven of the 31 studies 
examined infliximab trough levels, 20 examined levels of 
antibodies to infliximab and five and six studies, respec-
tively, investigated adalimumab levels and antibodies to 
adalimumab (table 1). The range of anti-TNF cut-offs 
used for the dichotomisation of test outcomes is illus-
trated in the online supplement 5 tables 1–3) . The risk 
of bias of studies varied. The greatest threat to validity was 
high risk of bias in patient selection, for example, studies 
did not enrol a consecutive or randomly selected patient 
group. This was present in nearly 80% of included studies 
(see online supplement  6 table 1 and figure 1).
The studies were heterogeneous with respect to the 
type of test used (eg, commercial or in-house ELISA, 
radioimmunoassay (RIA), homogeneous mobility shift 
assay (HMSA)), criteria for establishing response or lack 
of regaining response (eg, use of the Crohn’s Disease 
Activity Index score or the physician’s global assessment 
score) and population examined (responders or patients 
with secondary loss of response). Sensitivity and speci-
ficity pairs are summarised in figure 2 for antibodies to 
anti-TNF and figure 3 for anti-TNF trough levels.
The paired forest plots show that sensitivity and speci-
ficity of using anti-TNFs or antibodies produced against 
anti-TNFs to predict response or LOR vary greatly among 
studies with sensitivity revealing generally greater vari-
ation. Sensitivity analysis suggests that assay type may 
explain some of the variation in results between studies 
of anti-infliximab antibodies; however, there was consid-
erable heterogeneity between numerous study covariates 
(population, assay type, response criterion), and we do 
not know whether these might fully explain the large 
differences in results between studies.
Infliximab trough level tests for lor or lack of regaining 
response
Of 11 included studies, 2 were reported only as abstracts 
(Ben-Basset et al17 and Yanai et al18). The meta-anal-
ysis (figure 4) yielded a pooled summary point of 66% 
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Table 1 Major features of studies included for hierarchical meta-analyses
Study Drug Diagnosis Response/LOR Test Response measure
Trough antibodies to infliximab as predictor of loss of or lack of regaining response
Ben-Horin et al62 IFX ADA IBD~0.9 CD LOR ELISA PJ
Candon et al63 IFX CD LOR ELISA UC
Pariente et al64 IFX CD and UC LOR ELISA PJ or HBI
Baert et al65 IFX IBD~0.8 CD LOR HMSA PJ
Vande Casteele et al24 IFX IBD~0.70 CD LOR HMSA CRP TC
Ainsworth et al66 IFX CD LOR RIA PJ
Steenholdt et al26 IFX CD LOR RIA CDAI
Farrell et al67 IFX CD Resp ELISA PJ
Hanauer et al25 IFX CD Resp ELISA CDAI
Imaeda et al27 IFX CD Resp ELISA CDAI
Kong et al19 abstract IFX IBD~0.83 CD Resp ELISA PJ
Kopylov et al40 IFX CD Resp ELISA PJ
Marzo et al20 abstract IFX NR Resp ELISA CDAI
Nagore et al21 abstract IFX IBD~0.86 CD Resp ELISA PJ
Steenholdt et al68 IFX CD Resp ELISA PJ
Bodini et al22 abstract IFX CD Resp HMSA HBI
Vande Casteele et al24 IFX IBD~0.70 CD Resp HMSA CRP TC
Steenholdt et al69 IFX CD Resp RIA PJ ST
Ben-Horin et al70 IFX IBD~0.82 CD Resp NR ST
Dauer et al23 abstract IFX IBD~0.83 CD Resp NR PJ
Trough antibodies to adalimumab as predictor of loss of or lack of regaining response
Imaeda et al28 ADA CD Resp ELISA CRP
Mazor et al71 ADA CD Resp ELISA PJ+CRP
Roblin et al72 ADA CD Resp ELISA CDAI
Frederiksen et al73 ADA IBD Resp RIA PJ BM
West et al74 ADA CD Resp RIA PJ
Ben-Horin et al62 IFX ADA IBD~0.9 CD LOR ELISA SA
Infliximab trough level as predictor of loss of or lack of regaining response
Ainsworth et al66 IFX CD LOR RIA PJ
Steenholdt et al26 IFX CD LOR RIA CDAI
Bortlik et al75 IFX CD Resp ELISA PJ
Cornillie et al76 IFX CD Resp ELISA CDAI
Hibi et al77 IFX CD Resp ELISA CDAI
Imaeda et al27 IFX CD Resp ELISA CDAI
Kopylov et al40 IFX CD Resp ELISA PJ
Yanai et al18 abstract IFX CD Resp ELISA PJ
Ben-Basset et al17 abstract IFX IBD~0.93 CD Resp HMSA HBI
Steenholdt et al69 IFX CD Resp RIA PJ
Maser et al78 IFX CD Resp ELISA HBI
Adalimumab trough level as predictor of loss of or lack of regaining response
Chiu et al39 ADA CD LOR ELISA CDAI
Imaeda et al28 ADA CD Resp ELISA CRP
Mazor et al71 ADA CD Resp ELISA PJ+CRP
Roblin et al72 ADA CD Resp ELISA CDAI
Frederiksen et al73 ADA IBD Resp RIA PJ BM
ADA, adalimumab; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index score; CRP, C reactive protein level; Diagnosis, study patient population; HBI, 
Harvey Bradshaw Index score; HMSA, homogenous mobility shift assay; IBD, inflammatory bowel disease; IFX, infliximab; LOR, patients with loss of response; 
NR, not reported; PJ, physicians’ judgement; PJ BM, physicians’ judgement and biological measure; Resp, responding patients; Response measure, method 
used for defining clinical response; RIA, radioimmunoassay; SA, switch anti-TNF; ST, stop anti-TNF; TC, treatment change.
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Figure 2 Paired forest plots for anti-TNF antibody levels for predicting loss of response or failure to regain response 
to infliximab (top) and adalimumab (bottom). CDAI, Crohn’s Disease Activity Index score; CRP, C reactive protein level; 
HBI, Harvey Bradshaw Index score; HMSA, homogeneous mobility shift assay; LR, patients with loss of response; PJ, 
physicians’ judgement; PJ BM, physicians’ judgement and biological measure; POP, study patient population; R, patients with 
response; RES, criterion for determining clinical response; RIA, radioimmunoassay; RS, restart anti-TNF after drug holiday; SA, 
switch anti-TNF; ST, stop anti-TNF therapy; TC, treatment change; UC, unclear.
Figure 3 Paired forest plots for trough anti-tumour necrosis factor levels for predicting loss of response or failure to regain 
response to infliximab (top) and adalimumab (bottom). CDAI, Crohn’s Disease Activity Index score; CRP, C reactive protein level; 
HBI, Harvey Bradshaw Index score; HMSA, homogeneous mobility shift assay; LR, patients with loss of response; MH, mucosal 
healing; PJ, physicians’ judgement; PJ BM, physicians’ judgement and biological measure; POP, study patient population; R, 
patients with response; RES, criterion for determining clinical response; RIA, radioimmunoassay; UC, unclear.
sensitivity and 81% specificity (other test accuracy statistics 
are summarised in the online supplement 3). Sensitivity 
analysis in which only studies of responder populations 
were included generated very similar results as did anal-
ysis that only included studies with ELISA tests.
Antibodies to infliximab tests for lor or lack of regaining 
response
Of 20 included studies, 5 were reported as abstracts.19–23 
Sensitivity and specificity pairs are summarised in 
figure 5. The pooled summary points for sensitivity and 
specificity were 56% and 79%, respectively (figure 5). 
Only minor differences were introduced in the test 
accuracy outcomes (eg, 60% and 81% for sensitivity and 
specificity, respectively) in a sensitivity analysis when two 
influential studies were omitted from the analysis.24 25 
Sensitivity analyses in which only responder studies were 
included had little effect. Sensitivity analysis in which 
only ELISA studies were included showed an improve-
ment in specificity at the expense of sensitivity and a 
group.bmj.com on July 18, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Freeman K, et al. BMJ Open 2017;7:e014581. doi:10.1136/bmjopen-2016-014581
Open Access 
Figure 4 Hierarchical meta-analysis of trough infliximab 
levels for predicting loss of response or failure to regain 
response. Left, all 11 studies; right, responder studies only 
(n=9). The square symbol represents the summary point 
estimate on the hierarchical summary receiver operating 
characteristic (HSROC) curve. 
Figure 5 Hierarchical meta-analysis of trough levels of antibodies to infliximab for predicting loss of response or failure to 
regain response. Top left, all 20 studies; top right, ELISA studies only (n=9); lower left, all studies minus two influential studies 
(n=18)26 66; lower right, responder studies only (n=13). The square symbol represents the summary point estimate on the 
hierarchical summary receiver operating characteristic (HSROC) curve.
reduction in the heterogeneity of specificity measure-
ments (figure 5).
Adalimumab or anti-adalimumab antibody levels as tests for 
lor or lack of regaining response
Far fewer studies of adalimumab-treated patients were 
available compared with infliximab (table 1). Meta-anal-
ysis of patients treated with adalimumab yielded slightly 
lower test accuracy statistics with wider uncertainty 
around them compared with those found for infliximab 
studies (see online supplement 7 table 1 and figure 1).
combined assessment of anti-tnF levels and antibodies to 
anti-tnF
Three independent studies reported both drug and 
antibody test results by individual in relation to the indi-
vidual’s clinical status, response/LOR26 27 or regaining 
response/not regaining response.28 These studies 
allowed calculation of the number of patients in each 
of the two clinical states distributed to each of the four 
possible combinations of test result.26–28 The results 
summarised in tables 2 and 3 indicate the probability of 
LOR to anti-TNF, and table 4 summarises the probability 
of not regaining response to infliximab according to each 
possible test result category. These test results are reason-
ably similar to those from our meta-analysis of single test 
studies. This comparison should be viewed in the light of 
the considerable uncertainty which exists because of the 
small number of studies measuring both drug and anti-
body levels in the same individuals and their small size.
Predictive values of drug and antidrug antibody tests for lor 
or failure to regain response
In the Cochrane Handbook for Systematic Reviews of 
Diagnostic Test Accuracy, Bossuyt et al (2013)14 suggest 
that predictive values are more widely and readily 
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Table 2 Combined assessment of adalimumab and anti-
adalimumab levels for responders receiving adalimumab
Imaeda 
et al28 ADAbs+ ADAbs− Total
Population and 
anti-TNFα 
therapy; tests
Anti-
TNFα−
LOR=8 LOR=2 LOR=10 Responders on 
adalimumab 
maintenance;
ELISA. 
Prevalence of 
LOR=37.5%
RESP=0 RESP=2 RESP=2
Anti-
TNFα+
LOR=2 LOR=3 LOR=5
RESP=4 RESP=19 RESP=23
Total LOR=10 LOR=5 LOR=15
RESP=4 RESP=21 RESP=25
The probability of a patient returning each of the four possible test 
result combinations was:
ADAbs+/anti-TNFα−, 0.200; ADAbs+/anti-TNFα+, 0.150; ADAbs−/
anti-TNFα−, 0.10; ADAbs−/anti-TNFα+, 0.550.
The probabilities of losing response according to the category of 
test result were 1.00, 0.333, 0.500 and 0.136, respectively.
ADAbs, antidrug antibodies; ; LOR, loss of response; RESP,  
responders; ; TNF, tumour necrosis factor. 
Table 3 Combined assessment of infliximab and anti-
infliximab for responders receiving infliximab
Imaeda 
et al27 ADAbs+ ADAbs− Total
Population 
and anti-TNFα 
therapy; tests
Anti-
TNFα−
LOR=9 LOR=0 LOR=9 Responders 
on infliximab 
maintenance;
ELISA. 
Prevalence of 
LOR=29.3%
RESP=1 RESP=7 RESP=8
Anti-
TNFα+
LOR=3 LOR=5 LOR=8
RESP=3 RESP=30 RESP=33
Total LOR=12 LOR=5 LOR=17
RESP=4 RESP=37 RESP=41
The probability of a patient returning each of the four possible test 
result combinations was:
ADAbs+/anti-TNFα−, 0.172; ADAbs+/anti-TNFα+, 0.103; ADAbs−/
anti-TNFα−, 0.121; ADAbs−/anti-TNFα+, 0.603.
The probabilities of losing response according to the category of 
test result were 0.900, 0.500, 0.000 and 0.143, respectively.
ADAbs, antidrug antibodies; ; LOR, loss of response; RESP, 
responders; TNF, tumour necrosis factor.
appreciated than alternative test accuracy statistics such 
as sensitivity and specificity. Negative and positive predic-
tive values vary according to prevalence of the condition 
being tested for (in this case lack of response). We have 
meta-analysed the prevalence across the included studies 
and used this with its 95% CI as a guide to the approxi-
mate prevalence in which the tests would be performed 
in practice. The predictive values for each type of test 
across the relevant prevalence ranges are summarised in 
figure 6. As prevalence increases, positive predictive value 
increases and negative predictive value decreases.
Although pooled prevalence varies somewhat among 
the four collections of studies, the resulting positive and 
negative predictive values are similar and range between 
about 70% and 80% implying that between 20% and 30% 
of positive and negative test results are likely to be incor-
rect.
In January 2017, we updated our included studies 
by searching all citations of, and included studies in, 
five relevant systematic reviews (see online supple-
ment 2 figure 1).6 7 29–31 After removal of duplicates and 
the application of our inclusion criteria, this yielded 
three32–34 and five33 35–38 additional studies, respectively, 
for trough infliximab and trough adalimumab levels 
(see online supplement 8 table 1). Addition of the former 
to our meta-analysis had almost no influence on our esti-
mates of test accuracy (see online supplement 8 figures 
1 and 2 and table 2); the addition of the adalimumab 
studies to our meta-analysis also had very little influence 
on our estimates of test accuracy except a modest reduc-
tion in their uncertainty despite doubling the number of 
available studies (see online supplement 8 figures 1 and 3 
and table 3).
dIscussIon
The meta-analysis results indicate that the accuracy of 
tests for predicting lack of response was moderate and 
that about 20%–30% of both positive and negative test 
results are likely to be incorrect, with large unexplained 
heterogeneity between studies. The number of studies on 
patients treated with adalimumab was too small to draw 
firm conclusions, but the available evidence suggests 
similar performance to the tests for infliximab and for 
antibodies to infliximab.
The sensitivity analyses indicated that much of the 
variation seen in the forest plots and ROC space could 
not be explained by our measures of test type and popu-
lation. Test performance is dependent on cut-offs used 
for anti-TNF and antibodies to anti-TNF agents and on 
the time of testing. However, this was not investigated 
in sensitivity analyses as cut-offs vary by test type as well 
as within different types of tests, and an agreed cut-off 
that is transferable between studies and populations 
has yet to be identified. Furthermore, time of testing 
was not investigated as all but one study39 reported that 
anti-TNFs levels considered in the studies were trough 
levels.
Updating the searches found an extra seven studies; 
however, these made no meaningful difference to the 
test accuracy estimates. The study designs were largely 
similar to those in the previous studies. However, there 
appears to have been a recent waning of interest in 
antidrug antibodies, possibly attributable to publica-
tion of studies indicating their transitory and varying 
persistence during treatment, while interest in endo-
scopic healing as an outcome appears to have increased. 
Additional single arm test accuracy studies may not add 
significant further understanding in this field. Of more 
value would be head-to-head test accuracy comparisons 
in the same population and studies integrating drug 
levels with other predictive factors to enable more accu-
rate predictions of LOR.
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Table 4 Combined assessment of infliximab and anti-infliximab for people with loss of response receiving infliximab
Steenholdt et al26 ADAbs+ ADAbs− Total
Population and anti-TNFα 
therapy; tests
Anti-TNFα− NOR=8 NOR=2 NOR=10 Failure on infliximab, continued 
failure or gain of response at 
12 weeks; 
RIA. Prevalence of NOR=44.9%
RESP=6 RESP=1 RESP=7
Anti-TNFα+ NOR=1 NOR=20 NOR=21
RESP=3 RESP=28 RESP=31
Total NOR=9 NOR=22 NOR=31
RESP=9 RESP=29 RESP=38
The probability of a patient returning each of the four possible test result combinations was:
ADAbs+/anti-TNFα−, 0.203; ADAbs+/anti-TNFα+, 0.058; ADAbs−/anti-TNFα−, 0.00.043; ADAbs−/anti-TNFα+, 0.696.
The probabilities of failing to gain a response according to category of test result were 0.571, 0.250, 0.667 and 0.417, respectively.
ADAbs, antidrug antibodies; LOR, loss of response; RESP, responders; NOR, no regain of response; TNF, tumour necrosis factor. 
Figure 6 Positive predictive value (PPV) and negative predictive value (NPV) according to the prevalence of lack of response 
using the pooled summary receiver operating characteristic (sROC) model estimates of sensitivity and specificity. Data points, 
PPV and NPV at sROC pooled sensitivity and specificity and pooled prevalence; vertical dashed lines, pooled prevalence and 
95% CIs; thick curves, PPV and NPV at upper and lower CIs for sensitivity and specificity across the pooled prevalence and its 
95% CI. The dashed line ellipses encompass predictive values determined from 95% CIs of prevalence and 95% CI for PPV and 
NPV at the point prevalence estimate. 
Our meta-analyses included studies using different 
tests for measuring levels of anti-TNF agents and anti-
bodies to anti-TNFs. Although RIA and HMSA tests were 
used in some of our included studies, the bulk of the tests 
employed were ELISA tests (26/42, 62%) encompassing 
various commercial ELISA kits and ELISAs developed 
‘in house’ by investigators. Several full publications and 
abstracts have addressed the issue of whether different test 
methods (eg, solid phase ELISAs, liquid phase assays such 
as RIA or HMSA) deliver the same quantitative estimates 
of drug and antibody levels in patient samples.22 24 26–28 40–59 
Because there is no consensus about what constitutes a 
gold standard test, it is difficult to draw conclusions from 
these studies other than that some differences in perfor-
mance have been documented. Interestingly, the observed 
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variation in our meta-analysis could not be explained by the 
different tests used.
Although the accuracy of the tests for predicting 
lack of response was found to be moderate, this does 
not necessarily mean they must lack clinical utility. 
However, clinicians are likely to be interested in a 
combined assessment of anti-TNF levels and antibodies 
to anti-TNF, for which limited accuracy data are avail-
able.26–28 Diagnostic tests may alter clinical decisions and 
actions, so evidence beyond test accuracy is required to 
evaluate clinical value.60 Such evidence is best obtained 
in randomised trials (ie, test and treat investigations), 
but this is currently sparse.60
Two recent randomised controlled trials (RCTs) have 
compared clinical outcomes between patients whose treat-
ment was directed by algorithms informed by tests for 
infliximab and/or antibodies to infliximab versus patients 
who received treatment uninformed by testing.26 61 In the 
TAXIT trial,61 patients with inflammatory bowel disease 
responding to infliximab had their dose regimen optimised 
according to a test algorithm with the aim to bring patients 
within the therapeutic range and prevent LOR. However, 
after randomisation to clinically based or test-based dosing, 
no clinical benefit was observed for patients with CD at 1 year. 
Steenholdt et al (2014)26 investigated patients who had lost 
response to infliximab, using a test algorithm to predict 
the reason for LOR and adjust treatment accordingly. In 
this equivalence study, no difference in clinical benefit 
was observed for the test-algorithm group relative to the 
control group who were prescribed dose intensification. It 
is notable in this study that for many patients (14/33; 42%), 
clinicians failed to implement the test-algorithm directive, 
implying that they may have lacked confidence in the test 
results or that they considered other factors of overriding 
importance, as pointed out by Ferrante di Ruffano et al 
(2012).60 Such phenomena (lack of equipoise) complicate 
assessments of test value. Both of these RCTs reported cost 
savings in the test-algorithm arm associated with reduced 
use of infliximab.
This is the first meta-analysis of predictive accuracy of 
these tests and offers an alternative perspective to earlier 
meta-analyses. We were able to include more studies than 
in earlier meta-analyses and have looked at both drug tests 
and tests for antidrug antibodies and have included studies 
of patients receiving either infliximab or adalimumab ther-
apies. There was significant heterogeneity between studies, 
including in the test, outcome measurement and findings, 
making clinical interpretation difficult.
The meta-analysis results should be viewed with some 
caution because of the high risk of bias in many of the 
included studies and because the lack of sufficient 
numbers of studies precluded subgroup meta-analyses of 
some types of test (eg, RIA, HMSA).
conclusIons
The available evidence suggests that these tests have 
modest predictive accuracy for clinical status and that 
about 20%–30% of test results would be likely to be 
incorrect. However, higher quality head-to-head test 
accuracy studies are required to enable differentiation 
between different types of tests and cut-offs, with consis-
tent outcome measurement in the same population. In 
published trials, the tests have been used for adjusting 
dose or treatment of patients whose clinical status has 
already been defined by other criteria. More clinical trial 
evidence from test–treat studies is required before the 
clinical utility of the tests can be reliably evaluated.
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